Elacridar

Elacridar

CAT N°: 18128
Price:

From 48.00 40.80

Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM.{29372} Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain.{29371} This compound is effective against both human BCRP and the mouse homolog, Bcrp1.{29369,29370}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide
  • Correlated keywords
    • 143851-98-3 178436-75-4 143851-84-7 biochemical inhibitor cancer toxicology inhibit GF 129018 GF129018 GF-120918 GG-918 GW0918 MRP-1 BCRP MRP1 P-glycoprotein breast cancer resistance protein
  • Product Overview:
    Elacridar is a dual inhibitor of P-glycoprotein (MRP-1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). It maximally inhibits P-glycoprotein in isolated human peripheral blood leukocytes at 200 nM.{29372} Elacridar blocks the activity of P-glycoprotein at the blood-brain barrier, altering the pharmacokinetics of certain drugs in the brain.{29371} This compound is effective against both human BCRP and the mouse homolog, Bcrp1.{29369,29370}

We also advise you